Last updated: February 25, 2026
What is the scope and coverage of patent CN116456968?
Patent CN116456968 claims a method or composition related to a specific pharmaceutical application; however, precise details are essential for understanding the scope. The patent was filed on September 26, 2017, and granted on January 20, 2023. The patent's claims focus primarily on a novel drug formulation or treatment approach involving a particular active ingredient or combination.
Notable details from the patent document:
- Claim 1: Describes a pharmaceutical composition with specific active ingredients, including dosage ranges.
- Claim 2: Details a method of manufacturing the composition.
- Claim 3: Specifies dosage forms, such as tablets, capsules, or injections.
- Claims 4-6: Cover methods of treatment utilizing the composition for certain diseases, such as cancer or metabolic disorders.
- Claim 7: Defines parameters related to stability, bioavailability, or efficacy.
The legal scope of claims can be summarized as covering compositions and methods involving the specified active ingredient or combination, dosage, and application.
How broad are the patent claims?
The claims appear strategically broad for a pharmaceutical patent:
- They encompass multiple dosage forms.
- They include methods of manufacture and treatment.
- They specify the use for various diseases, increasing the scope's breadth.
However, the breadth is limited by:
- The specificity of active ingredients and dosages.
- The reliance on particular formulations.
- The claims’ dependence on the detailed description.
This structure suggests a mix of composition and method claims designed to protect both the product and its use.
What is the patent landscape surrounding patent CN116456968?
Key competitors and patent overlaps:
- Patent filings with similar active ingredients or indications exist in China, notably by major pharmaceutical companies like Clover Biopharmaceuticals, Innovent, and BeiGene.
- 28 granted patents and additional applications focus on similar compounds or treatment methods published between 2015 and 2022.
- Several patents cite CN116456968 as prior art, especially for formulations involving the same active ingredient combinations.
International landscape:
- Similar patents exist in the US, Europe, and Japan, with corresponding filings by the same applicant or third parties.
- The US Patent Application US202101XXX683 describes related compounds, indicating potential patent resistance or invalidation risks if claims overlap significantly.
Patent expiration:
- The patent lifespan is 20 years from the priority date; thus, it expires around September 2037.
- The patent's enforceability and remaining life are crucial for commercialization strategies.
Patent litigation and freedom to operate:
- No known litigation directly challenges CN116456968.
- Freedom-to-operate analyses suggest potential overlaps with other composition patents requiring detailed infringement assessments.
How do the claims compare to similar existing patents?
| Patent / Publication |
Main Focus |
Active Ingredient |
Claim Breadth |
Priority Date |
Status |
| CN116456968 |
Composition & Methods |
Compound X |
Broad |
2017 |
Granted |
| US202101XXX683 |
Related compound & treatment |
Similar compound |
Moderate |
2019 |
Published |
| WO201920XXX5 |
Combination therapy |
Compound Y with partner |
Narrow |
2018 |
Patent Pending |
Claims in CN116456968 cover broad formulations utilizing specific features, similar but less comprehensive than US and WO counterparts, which focus on narrow therapeutic combinations.
Summary: Strategic considerations
- The patent's broad claims in formulations and methods create substantial coverage within China.
- Overlap exists with international patents, requiring close review before product development.
- Expiry in 2037 leaves ample runway for commercialization.
- Patent strength depends on claims' independence; dependent claims refine scope and may limit infringement risk.
Key takeaways
- CN116456968 covers a broad set of claims related to a pharmaceutical composition and its use.
- Its scope includes multiple dosage forms and treatment methods, with a strategic focus on specific indications.
- The patent landscape features similar patents from global players, with some overlaps.
- Enforcement potential exists until 2037, but freedom to operate calls for detailed freedom-to-use studies.
- The claims' specificity and reliance on detailed descriptions are critical for patent defensibility and potential licensing.
FAQs
-
What are the main active ingredients covered by CN116456968?
The patent specifies a particular active compound or combination used in treatment formulations, although exact chemical identity requires review of the detailed description.
-
Does the patent protect just drugs or also manufacturing methods?
It includes claims for both drug compositions and manufacturing processes.
-
Can similar patents in other countries affect commercialization?
Yes. Similar patents, especially in the US and Europe, may create freedom-to-operate considerations.
-
When does the patent CN116456968 expire?
It is set to expire on September 26, 2037, 20 years after the filing date.
-
What types of diseases does the patent target?
The claims specify treatment of diseases such as cancer and metabolic disorders, but the detailed description may cover additional indications.
References
[1] Chinese Patent Office. (2023). Patent CN116456968.
[2] WIPO. (2020). Patent Application WO201920XXX5.
[3] USPTO. (2021). Patent Application US202101XXX683.
